BSX at a glance
Boston Scientific (BSX, SEC CIK 885725) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on September 23, 2026 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Boston Scientific (BSX) reported revenue of $20.1 billion (up 19.9% from FY2024) and net income of $2.9 billion. Diluted EPS was $1.94.
- As of June 30, 2026, 44 institutional investment managers tracked by SignalX reported holding Boston Scientific (BSX) shares worth $25.3 billion in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Morano Susan E on August 25, 2026 of 2,040 shares at $49.22 per share.
- In the last 90 days, BSX insiders reported 6 open-market purchases ($9.5M) and 0 open-market sales ($0) on Form 4, a net purchase of $9.5M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $20.1B
- +19.9% vs prior year
- Insiders · 90 days
- 6 buys · 0 sells
- Net +$9.5M
- 13F holders
- 44 funds
- $25.3B · −5 vs prior quarter
- Latest 8-K
- Sep 23, 2026
- Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Medical devices portfolio across Endoscopy, Urology, Neuromodulation, MedSurg, and Cardiovascular segments
- Cardiovascular strategic shift: Discontinued ACURATE Neo2/Prime Aortic Valve sales globally, ceased pursuit of FDA and other approvals in 2025
- Notable new acquisitions emphasized: Axonics (Urology), Silk Road Medical and Intera (Cardiovascular), Braun vacuum therapy (Endoscopy)
- Quantitative highlight: Net sales increased 19.9% to $20.1B in 2025, R&D spend rose 27% to $2.05B, SG&A expenses up 15%
- Unusual fact: $194 million litigation charge in 2025 due to resolution of legacy IP claim tied to acquisition
Risk Factors
- Leverage ratio maximum 4.50x as of December 31, 2025, up from 3.75x pre-Axonics acquisition in November 2024
- Total debt $11.436B at end of 2025, up from $10.746B in 2024, fixed-rate debt $11.393B versus variable $43M
- No restructuring charge exclusion remaining after using $500M limit; litigation exclusion $1.160B remaining under credit agreement
- Qualified Acquisition leverage step-down schedule triggered by $1B+ Axonics purchase with elevated ratios through seven quarters
- Current debt $299M sharply down from $1.778B in 2024, reflecting liability management or refinancing activities
Management Discussion & Analysis
- No revenue, profitability, segment, or cash flow data disclosed in provided MD&A section
- Management implementing new global ERP affecting internal controls, phased rollout began August 2025 in EMEA
- Senior HR officer initiated a Rule 10b5-1 trading plan for sale of 14,912 shares, effective through Dec 31, 2026
- No forward-looking guidance, risks, or financial outlook information included in the disclosed text
AI summary of the BSX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Headwinds: foreign exchange, tariffs, geopolitical conflicts, supply-chain disruptions, cybersecurity, labor costs
- Outlook risks: regulatory conditions, product launches, competition, reimbursement, acquisitions, procedural volumes, litigation
Risk Factors
- No material changes to 10-K risk factors disclosed
- Financial risk: $2.000 billion accelerated share repurchase reduced remaining authorization to $3.000 billion
AI summary of the BSX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Arthur C. Butcher retiring as Executive Vice President and Group President, MedSurg and Asia Pacific, effective January 1, 2027
- Senior-advisor transition through February 26, 2027, or earlier Retirement Date
Item 1.05: Material Cybersecurity Incidents
- Cybersecurity incident disrupted manufacturing, distribution, and customer-order processing globally
- Distribution centers largely restored, with major facilities shipping at or above normal levels
Item 8.01: Other Events
- Cybersecurity incident identified August 25, 2026, causing global operational disruption
- Limited systems access impairing customer-order processing and shipments
AI summaries of BSX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BSX
Don't miss the next BSX filing
- Alerts as it files. A push when BSX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BSX, by share count.
- Ask anything. An AI agent that reads every BSX filing and answers with sources.
BSX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| O'Connor Padraig Andrew | F | Sep 2, 2026 | 567 | $48.37 |
| O'Connor Padraig Andrew | M | Sep 2, 2026 | 1,171 | - |
| O'Connor Padraig Andrew | M | Sep 2, 2026 | 1,171 | - |
| Morano Susan E | Buy | Aug 25, 2026 | 2,040 | $49.22 |
| Woodworth Emily | I | Aug 11, 2026 | 2,930 | $51.19 |
| Monson Jonathan | I | Aug 10, 2026 | 9,908 | $50.46 |
| Habiger David C | Buy | Aug 5, 2026 | 2,100 | $47.59 |
| Habiger David C | Buy | Aug 4, 2026 | 140 | $48.59 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $16.7B | $20.1B |
| Gross Profit | - | $11.5B | $13.9B |
| Operating Income | - | $2.6B | $3.6B |
| Net Income | - | $1.9B | $2.9B |
| Gross Margin | - | 68.6% | 69.0% |
| Op. Margin | - | 15.5% | 18.0% |
| Net Margin | - | 11.1% | 14.4% |
| Balance Sheet | |||
| Total Assets | $35.1B | $39.4B | $43.7B |
| Equity | $19.3B | $21.8B | $24.2B |
| ROE | - | 8.5% | 12.0% |
| Per Share | |||
| EPS | - | $1.25 | $1.94 |
| Cash Flow | |||
| Operating CF | - | $3.4B | $4.5B |
| CapEx | - | $790.0M | $876.0M |
Source: XBRL data in Boston Scientific (BSX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate BSX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 44 | $25.31B |
| Q1 2026 | 49 | $39.42B |
| Q4 2025 | 50 | $61.15B |
| Q3 2025 | 50 | $67.84B |
| Q2 2025 | 48 | $71.83B |
| Q1 2025 | 45 | $53.10B |
| Q4 2024 | 38 | $38.75B |
| Q3 2024 | 31 | $14.34B |
- Two Sigma Investments+9.95M (+106%)
- Invesco Ltd+4.75M (+52%)
- AQR Capital Management+4.44M (+85%)
- State Street Corp+2.12M (+3%)
- D.E. Shaw & Co+1.15M (+5%)
- FMR LLC (Fidelity)−28.52M (-38%)
- Bank of America Corp−9.73M (-43%)
- JPMorgan Chase & Co−9.44M (-28%)
- Morgan Stanley−3.32M (-15%)
- BlackRock−2.14M (-2%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 355 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BSX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 23, 2026 | - | Analysis | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 8-K | Aug 26, 2026 | - | Analysis | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 8-K | Jul 27, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 1, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 8-K | May 18, 2026 | - | Analysis | |
| 8-K | May 18, 2026 | - | Analysis | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
BSX SEC filings: frequently asked questions
Are BSX insiders buying or selling?
In the last 90 days, Boston Scientific (BSX) officers, directors and 10% owners reported 6 open-market purchases worth $9.5 million by 4 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold BSX stock?
As of June 30, 2026, the largest Boston Scientific (BSX) holders among the 13F filers tracked by SignalX were BlackRock ($5.5 billion), Vanguard Capital Management LLC ($4.1 billion), State Street Corp ($3.0 billion), FMR LLC (Fidelity) ($2.0 billion), Vanguard Portfolio Management LLC ($1.3 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BSX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Boston Scientific (BSX) reported revenue of $20.1 billion (up 19.9% from FY2024) and net income of $2.9 billion. Diluted EPS was $1.94. The figures come from the XBRL data in the 10-K.
What are the main risks in BSX's latest 10-K?
In the 10-K filed February 17, 2026, Boston Scientific (BSX) flagged: Leverage ratio maximum 4.50x as of December 31, 2025, up from 3.75x pre-Axonics acquisition in November 2024. Total debt $11.436B at end of 2025, up from $10.746B in 2024, fixed-rate debt $11.393B versus variable $43M. (AI summary of the Risk Factors section.)
What did BSX report in its latest 8-K?
Boston Scientific (BSX) filed an 8-K on September 23, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Arthur C. Butcher retiring as Executive Vice President and Group President, MedSurg and Asia Pacific, effective January 1, 2027.
What are the latest BSX SEC filings?
Boston Scientific (BSX) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on September 23, 2026 and a Form 4 insider filing on September 3, 2026.
What is BSX's SEC CIK number?
Boston Scientific (BSX)'s SEC Central Index Key (CIK) is 885725. EDGAR lists every BSX filing under that number.
Ask anything about BSX
The research agent reads BSX's filings, financials, insider trades and 13F holders, then answers with sources.